Antibodies and Vaccines Against Botulinum Toxins: Available Measures and Novel Approaches - Archive ouverte HAL Access content directly
Journal Articles Toxins Year : 2019

Antibodies and Vaccines Against Botulinum Toxins: Available Measures and Novel Approaches

(1) , (1)
1

Abstract

Botulinum neurotoxin (BoNT) is produced by the anaerobic, Gram-positive bacterium Clostridium botulinum. As one of the most poisonous toxins known and a potential bioterrosism agent, BoNT is characterized by a complex mode of action comprising: internalization, translocation and proteolytic cleavage of a substrate, which inhibits synaptic exocytotic transmitter release at neuro-muscular nerve endings leading to peripheral neuroparalysis of the skeletal and autonomic nervous systems. There are seven major serologically distinct toxinotypes (A-G) of BoNT which act on different substrates. Human botulism is generally caused by BoNT/A, B and E. Due to its extreme lethality and potential use as biological weapon, botulism remains a global public health concern. Vaccination against BoNT, although an effective strategy, remains undesirable due to the growing expectation around therapeutic use of BoNTs in various pathological conditions. This review focuses on the current approaches for botulism control by immunotherapy, highlighting the future challenges while the molecular underpinnings among subtypes variants and BoNT sequences found in non-clostridial species remain to be elucidated.
Fichier principal
Vignette du fichier
Antibodies_and_vaccines_against_Botulims_toxins.pdf (951.11 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

pasteur-02453849 , version 1 (24-01-2020)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Christine Rasetti-Escargueil, Michel Popoff. Antibodies and Vaccines Against Botulinum Toxins: Available Measures and Novel Approaches. Toxins, 2019, 11 (9), pp.E528. ⟨10.3390/toxins11090528⟩. ⟨pasteur-02453849⟩

Collections

PASTEUR
28 View
212 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More